A study today in Infection Control & Hospital Epidemiology reports a high prevalence of antibiotic allergy labels (AALs) in Australian nursing homes.
A computerized clinical support tool implemented at an academic medical center helped reduce rates of Clostridioides difficile testing without an associated increase in adverse events in patients whose tests were prevented, researchers from the University of Virginia (UVA) School of Medicine reported today in Open Forum Infectious Diseases.
The drugs were linked to a more than 70% increase in the odds of intestinal colonization with resistant bacteria.
A major reduction in the use of fluoroquinolones has driven a 12% decrease in total antibiotic use in Canadian hospitals in recent years, according to a new study in Antimicrobial Resistance and Infection Control.
According to the World Health Organization's (WHO's) online Ebola dashboard, only one new case of Ebola has been recorded in the Democratic Republic of the Congo (DRC) since Feb 6, raising the outbreak total to 3,431 confirmed cases. The WHO also noted 123 probable cases, and 441 suspected cases still under investigation.
Since the outbreak in North Kivu and Ituri provinces began in August 2018, 2,249 people have died from Ebola.
After US flu activity peaked at the end of 2019 and fell for 2 straight weeks, it has now increased measurably for the second straight week, while the number of flu-related deaths in children rose by 14, to 68, the Centers for Disease Control and Prevention (CDC) said in its weekly FluView report today.
The World Health Organization's (WHO's) online Ebola dashboard shows two newly confirmed cases of the virus in the Democratic Republic of the Congo (DRC). The outbreak totals now stand at 3,418 cases, including 2,240 deaths. A total of 494 suspected cases are still under investigation.
Yesterday the DRC's Ebola technical committee (CMRE) confirmed that one of the new cases was located in Beni.
Summit Therapeutics yesterday announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded the company an additional $8.8 million for clinical and regulatory development of an investigational antibiotic for treating Clostridiodes difficile infection (CDI).
In a surprising finding, pet ownership and increasing contact with pets may be protective against the recurrence of community-acquired Clostridiodes difficile infection (CDI), researchers from the University of Pennsylvania reported recently in Open Forum Infectious Diseases.
CARB-X today said it has awarded Trellis Bioscience of Redwood City, California, up to $3.2 million to develop an innovative monoclonal antibody designed to disrupt the protective biofilm that makes bacteria resistant to antibiotics.